Meta AnalysisID 362
黄芪治疗糖尿病肾病的随机对照试验系统评价
CRD42017081403
Is Astragalus membranaceus effective for diabetic kidney disease (DKD) in terms of mortality? Is Astragalus membranaceus effective for DKD in terms of progression to end-stage kidney disease? Is Astragalus membranaceus
Relationship Network
Interactive first-hop connections across herbs, ingredients, formulas, targets, diseases, symptoms, syndromes, evidence, and monographs.
Click a node to open it in a new tab
Herb: 1Meta-analysis: 1Links: 1
Arranging relationship network...
Record Fields
Scalar fields from the final meta_analysis record.
- Meta Analysis Id
- 362
- Evidence Id
- 8920
- Core Evidence Id
- 8920
- Source Meta Analysis Id
- 341
- Herb2 Meta Analysis Id
- HBMA000341
- Crd Id
- CRD42017081403
- Title
- Astragalus membranaceus (Huang qi) for diabetic kidney disease: a systematic review of randomised controlled trials
- Review Question
- Is Astragalus membranaceus effective for diabetic kidney disease (DKD) in terms of mortality? Is Astragalus membranaceus effective for DKD in terms of progression to end-stage kidney disease? Is Astragalus membranaceus effective for DKD in terms proteinuria and albuminuria? Is Astragalus membranaceus effective for DKD in terms of change in kidney function? Is Astragalus membranaceus effective for DKD in terms quality of life? Is Astragalus membranaceus safe for people with DKD?
- Study Type Included
- Randomised controlled trials.
- Condition Being Studied
- Diabetic kidney disease; diabetic nephropathy.
- Participant
- Adults (age over 18 year-old) with diabetic kidney disease induced by primary diabetes.
- Animal
- Human Disease Modelled
- Intervention
- Astragalus membranaceus products solely used on the basis of DKD conventional treatments. Any form of Astragalus membranaceus (Huang qi) preparation, including water decoction, extracts, granules or injection will be included. Astragalus agent or formula with other compounds or ingredients will be excluded.
- Comparator Control
- Placebo, conventional pharmacotherapy.
- Main Outcome
- 1. All-cause mortality. 2. Number of patients progressing to end-stage kidney disease (ESKD). 3. Change in kidney function (measured by GFR or serum creatinine concentration or creatinine clearance). 4. Albuminuria (measured by Urine albuminuria creatinine ratio, albuminuria excretion rate or albuminuria concentration). 5. Proteinuria (measured by Urine proteinuria creatinine ratio, proteinuria excretion rate or proteinuria concentration). 6. Adverse events.
- Outcome Measure
- Additional Outcome
- 1. Quality of life. 2. Indicators of risk factor control: fasting blood glucose, HbA1c, systolic BP, diastolic BP, total cholesterol, LDL cholesterol, HDL cholesterol, triglycerides, uric acid concentration.
- Study Method
- Intervention, Meta-analysis
- Keyword
- Astragalus Plant; Astragalus membranaceus; Diabetic Nephropathies; Drugs, Chinese Herbal; Huang Qi; Humans; Juglandaceae
- Contact
- La Zhang [email protected]
- Organisational Affiliation
- Guangdong Provincial Hospital of Chinese Medicine; RMIT university https://www.rmit.edu.au/research/research-institutes-centres-and-groups/multi-partner-collaborations/cairccm
- Funding Source
- China-Australia International Research Centre for Chinese Medicine (CAIRCCM).
- Other Selection Criteria
- Final Publication
- Same Topic Review
- Published Protocol
- Review Type
- Language
- English
- Country
- Australia, China
- Review Stage
- Review Ongoing
- First Submission Date
- 2017-11-13
- Registration Date
- 2017-12-07
- Anticipated Start Date
- 2017-10-23
- Anticipated Completion Date
- 2018-03-01
- Title Cn
- 黄芪治疗糖尿病肾病的随机对照试验系统评价
- Title En
- Astragalus membranaceus (Huang qi) for diabetic kidney disease: a systematic review of randomised controlled trials
- Bilingual Status
- complete